17,261 trials
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes · Lymphoma, Non-Hodgkin
Primary: Number of Donors Requiring a Second Collection to Obtain a Minimum CD34/Kg (2 x 10^6) Necessary for Allogeneic Stem Cell Transplantation — 4 Participants
Multiple Sclerosis · Cognition
Primary: Paced Auditory Serial Addition Task (PASAT) — 2.24; 3.38 correct responses — p=0.05
Ovarian Clear Cell Cystadenocarcinoma · Stage III Ovarian Cancer · Stage IV Ovarian Cancer
Primary: Proportion of Patients Who Are Alive and Progression-free for at Least 12 Months After Study Entry in Patients With Newly Diagnosed Stage III or IV Clear Cell Ovarian…
Multiple Sclerosis
Primary: Proportion of Participants Confirmed as Improvement Responders for Primary Multicomponent Endpoint — 0.516; 0.511; 0.656; 0.688 proportion of participants — p=0.9584
Leukemia · Lymphoma
Primary: 2-year Progression-free Survival in Early Disease Participants — 79.5 percentage of participants
Food Hypersensitivity
Primary: The Amount of Peanut Protein Ingested Before An Allergic Reaction is Observed During the Double-blind, Placebo Controlled Food Challenge (DBPCFC) After Completing…
Neuroendocrine Tumors
Primary: Tumor Response Rate Measured by the Response Evaluation Criteria in Solid Tumors (RECIST) — 0; 0; 0; 8 participants
Neoplasms · Breast Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLT): Part 1 Phase 1 — 1; 1 Participants
Pain, Post-operative
Primary: Summed Pain Intensity Difference Over the First 48 Hours (SPID48). — -2328.2; -548.90 units on a scale — p=0.0180
Influenza
Primary: Number of Subjects With Haemagglutination Inhibition (HI) Antibody Concentrations Above the Cut-off Value — 28; 30 Subjects
Gout
Primary: Number of Gout Flares Per Participant Assessed From Day 1 to Day 84 (Week 12) — 0.79; 0.15 Number of gout flares per participant
Deep Vein Thrombosis · Fibrillation, Atrial · Venous Thromboembolism
Primary: Percentage of Participants With Total VTE Event Over 10 ± 2 Days of Treatment — 45.1; 44.4; 41.3; 31.2 Percentage of participants — p=0.012
Multiple Myeloma
Primary: Overall Response Rate — 95 percentage of participants
Lung Cancer
Primary: Overall Response Rate — 65; 50 percentage of participants
Atopic Dermatitis
Primary: IGA — 1 units on a scale